조직학 및 세포학 시장 보고서 : 제품 유형별, 검사 유형별, 테스트 유형별, 용도별, 지역별(2026-2034년)

The global histology and cytology market size reached USD 19.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 43.1 Billion by 2034, exhibiting a growth rate (CAGR) of 8.69% during 2026-2034. The increasing demand for early disease detection, along with the rising awareness about advanced therapeutics, is propelling the market.

HISTOLOGY AND CYTOLOGY MARKET ANALYSIS:

• Major Market Drivers: The growing advancements in diagnostic technology are making these tests more efficient, thereby propelling the market.
• Key Market Trends: The rising awareness about cancer screening is leading to higher utilization of these tests, which is acting as a significant growth-inducing factor.
• Competitive Landscape: Some of the major market companies include Abbott Laboratories, Becton Dickinson and Company, Carl Zeiss AG, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., Koninklijke Philips N.V., Merck KGaA, Olympus Corporation, PerkinElmer Inc., Sysmex Corporation, Thermo Fisher Scientific Inc., and Trivitron Healthcare, among many others.
• Geographical Trends: North America exhibits a clear dominance in the market due to advanced healthcare infrastructure and rising cancer cases, along with the increasing demand for diagnostic services in pathology labs.
• Challenges and Opportunities: The limited accessibility and high costs are hindering the market. However, technological advancements and expanded training programs to improve efficiency and affordability will continue to strengthen the market over the forecast period.

HISTOLOGY AND CYTOLOGY MARKET TRENDS:

Technological Advancements in AI Integration

AI integration is transforming histology and cytology by enabling more precise analysis of pathology slides. Moreover, advanced imaging techniques paired with AI-driven tools improve the detection of abnormal cells, thereby reducing manual errors. Furthermore, these innovations streamline processes, thereby making diagnoses quicker and more reliable. Thus, benefiting laboratories and healthcare providers and driving histology and cytology market growth. For instance, in August 2024, Modella AI launched multimodal foundation models and generative AI copilots, including PathChat 2, to enhance diagnostic accuracy in pathology. These innovations revolutionize the market by automating tasks, improving efficiency, and integrating pathology images with clinical data for comprehensive analysis.

Improved Diagnostic Accuracy and Efficiency

Enhanced imaging technologies and automated workflows are increasing the accuracy of diagnoses in histology and cytology. In addition, faster detection of abnormalities ensures early intervention while reducing false negatives. Also, this results in better patient outcomes, as medical professionals can make more informed decisions with greater confidence and in less time. For instance, in February 2024, Hologic launched the FDA-cleared genius digital diagnostics system, the first digital cytology platform combining AI with advanced imaging for cervical cancer screening. It reduces false negatives by approximately 28%, improves workflow, and enables remote collaboration for enhanced diagnostic accuracy in histology and cytology.

Growing Demand for Digital Pathology Solutions

The need for scalable, remote, and secure solutions drives the shift towards digital pathology. In contrast, laboratories and healthcare institutions are adopting digital platforms for easy access to data, centralized workflows, and enhanced collaboration among professionals, which improves research and clinical efficiency while ensuring the secure handling of pathology information. For instance, in October 2024, HistoWiz launched its advanced FFPE block management solution as part of the PathologyMap 2.0 platform. This solution offers 24/7 digital access to tissue samples, secure storage, rapid histology services, and integrated workflows, enhancing efficiency and security in histology and cytology research.

GLOBAL HISTOLOGY AND CYTOLOGY INDUSTRY SEGMENTATION:

Breakup by Product:

• Instruments and Analysis Software System
• Consumable and Reagents

Consumable and reagents currently dominate the market

Consumables and reagents exhibit a clear dominance in the market, with significant growth driven by the regular need for replenishing consumables during diagnostic procedures. For example, Hologic's ThinPrep Pap Test reagents have become widely adopted in cytology for detecting cervical abnormalities.

Breakup by Type of Examination:

• Histology
• Cytology

Cytology currently dominates the market

Cytology, lead the market, which is driven by focusing on the study of individual cell structures, often surpasses histology in faster diagnostics. For example, fine needle aspiration cytology is widely used in cancer screening due to its minimally invasive nature and quick results.

Breakup by Test Type:

• Microscopy Tests
• Molecular Genetics Tests
• Flow Cytometry

Microscopy tests currently dominates the market

Microscopy tests dominate the market, offering precise cellular analysis. For example, Roche's Digital Pathology portfolio enhances efficiency by integrating AI in microscope testing, thereby helping pathologists detect abnormalities in tissue samples more accurately and quickly than traditional methods.

Breakup by Application:

• Drug Discovery and Designing
• Clinical Diagnostics
  • Point-of-Care (PoC)
  • Non-Point-of-Care
• Research

Drug discovery and designing currently hold the largest histology and cytology market share

Drug discovery and designing leads the market, as they play a significant role in histology and cytology by enabling the identification of cellular changes in response to new compounds. For instance, PerkinElmer's launch of advanced imaging systems accelerates these processes by providing detailed cellular analysis for drug development.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the market

The market outlook report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest histology and cytology market share.

North America dominates the market, which is driven by advanced healthcare infrastructure and high adoption of diagnostic technologies. In addition, the presence of key industry players, like Hologic and Becton Dickinson, fuels innovation and product launches. For example, Hologic's Panther Fusion system, offering advanced molecular diagnostics, highlights the region's focus on expanding diagnostic capabilities. Also, favorable government initiatives and a rising number of cancer cases support the market's growth, making North America a leader in histology and cytology advancements.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all market companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• Becton Dickinson and Company
• Carl Zeiss AG
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Hologic Inc.
• Koninklijke Philips N.V.
• Merck KGaA
• Olympus Corporation
• PerkinElmer Inc.
• Sysmex Corporation
• Thermo Fisher Scientific Inc.
• Trivitron Healthcare

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global histology and cytology market in 2025?

2. What is the expected growth rate of the global histology and cytology market during 2026-2034?

3. What are the key factors driving the global histology and cytology market?

4. What has been the impact of COVID-19 on the global histology and cytology market growth?

5. What is the breakup of the global histology and cytology market based on the product?

6. What is the breakup of the global histology and cytology market based on the type of examination?

7. What is the breakup of the global histology and cytology market based on test type?

8. What is the breakup of the global histology and cytology market based on the application?

9. What are the key regions in the global histology and cytology market?

10. Who are the key players/companies in the global histology and cytology market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Histology and Cytology Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Instruments and Analysis Software System
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Consumable and Reagents
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Type of Examination

• 7.1 Histology
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Cytology
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Test Type

• 8.1 Microscopy Tests
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Molecular Genetics Tests
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Flow Cytometry
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Application

• 9.1 Drug Discovery and Designing
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Clinical Diagnostics
  • 9.2.1 Market Trends
  • 9.2.2 Key Segments
    • 9.2.2.1 Point-of-Care (PoC)
    • 9.2.2.2 Non-Point-of-Care
  • 9.2.3 Market Forecast
• 9.3 Research
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbott Laboratories
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Becton Dickinson and Company
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Carl Zeiss AG
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 SWOT Analysis
  • 15.3.4 Danaher Corporation
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 F. Hoffmann-La Roche AG
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
    • 15.3.5.3 Financials
  • 15.3.6 Hologic Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
    • 15.3.6.3 Financials
    • 15.3.6.4 SWOT Analysis
  • 15.3.7 Koninklijke Philips N.V.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Merck KGaA
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Olympus Corporation
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 Financials
    • 15.3.9.4 SWOT Analysis
  • 15.3.10 PerkinElmer Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Sysmex Corporation
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis
  • 15.3.12 Thermo Fisher Scientific Inc.
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio
    • 15.3.12.3 Financials
    • 15.3.12.4 SWOT Analysis
  • 15.3.13 Trivitron Healthcare
    • 15.3.13.1 Company Overview
    • 15.3.13.2 Product Portfolio